Yue Qiu1, Liang Li1, Tian-yan Zhou1, Wei Lu1. 1. 1] State Key Laboratory of Natural and Biomimetic Drugs (Peking University), Beijing 100191, China [2] Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China.
Abstract
AIM: Biomarkers and image markers of Alzheimer's disease (AD), such as cerebrospinal fluid Aβ42 and p-tau, are effective predictors of cognitive decline or dementia. The aim of this study was to integrate these markers with a disease progression model and to identify their abnormal ranges. METHODS: The data of 395 participants, including 86 normal subjects, 108 early mild cognitive impairment (EMCI) subjects, 120 late mild cognitive impairment (LMCI) subjects, and 81 AD subjects were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. For the participants, baseline and long-term data on cerebrospinal fluid Aβ42 and p-tau, hippocampal volume, and ADAS-cog were available. Various linear and nonlinear models were tested to determine the associations among the ratio of Aβ42 to p-tau (the Ratio), hippocampal volume and ADAS-cog. RESULTS: The most likely models for the Ratio, hippocampal volume, and ADAS-cog (logistic, Emax, and linear models, respectively) were used to construct the final model. Baseline disease state had an impact on all the 3 endpoints (the Ratio, hippocampal volume, and ADAS-cog), while APOEε4 genotype and age only influence the Ratio and hippocampal volume. CONCLUSION: The Ratio can be used to identify the disease stage for an individual, and clinical measures integrated with the Ratio improve the accuracy of mild cognitive impairment (MCI) to AD conversion forecasting.
AIM: Biomarkers and image markers of Alzheimer's disease (AD), such as cerebrospinal fluid Aβ42 and p-tau, are effective predictors of cognitive decline or dementia. The aim of this study was to integrate these markers with a disease progression model and to identify their abnormal ranges. METHODS: The data of 395 participants, including 86 normal subjects, 108 early mild cognitive impairment (EMCI) subjects, 120 late mild cognitive impairment (LMCI) subjects, and 81 AD subjects were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. For the participants, baseline and long-term data on cerebrospinal fluid Aβ42 and p-tau, hippocampal volume, and ADAS-cog were available. Various linear and nonlinear models were tested to determine the associations among the ratio of Aβ42 to p-tau (the Ratio), hippocampal volume and ADAS-cog. RESULTS: The most likely models for the Ratio, hippocampal volume, and ADAS-cog (logistic, Emax, and linear models, respectively) were used to construct the final model. Baseline disease state had an impact on all the 3 endpoints (the Ratio, hippocampal volume, and ADAS-cog), while APOEε4 genotype and age only influence the Ratio and hippocampal volume. CONCLUSION: The Ratio can be used to identify the disease stage for an individual, and clinical measures integrated with the Ratio improve the accuracy of mild cognitive impairment (MCI) to AD conversion forecasting.
Authors: Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Liana G Apostolova; Rebecca A Dutton; Ivo D Dinov; Kiralee M Hayashi; Arthur W Toga; Jeffrey L Cummings; Paul M Thompson Journal: Arch Neurol Date: 2006-05
Authors: Maartje I Kester; Wiesje M van der Flier; Gorana Mandic; Marinus A Blankenstein; Philip Scheltens; Majon Muller Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: Leslie M Shaw; Magdalena Korecka; Christopher M Clark; Virginia M-Y Lee; John Q Trojanowski Journal: Nat Rev Drug Discov Date: 2007-03-09 Impact factor: 84.694
Authors: Davangere P Devanand; Gregory H Pelton; Kristina D'Antonio; Adam Ciarleglio; Jennifer Scodes; Howard Andrews; Julia Lunsford; John L Beyer; Jeffrey R Petrella; Joel Sneed; Michaela Ciovacco; Pudugramam Murali Doraiswamy Journal: Am J Geriatr Psychiatry Date: 2018-06-28 Impact factor: 4.105
Authors: Anna Plachti; Shahrzad Kharabian; Simon B Eickhoff; Somayeh Maleki Balajoo; Felix Hoffstaedter; Deepthi P Varikuti; Christiane Jockwitz; Svenja Caspers; Katrin Amunts; Sarah Genon Journal: Brain Date: 2020-09-01 Impact factor: 13.501